Navigation Links
Optimer Reports First Quarter 2013 Financial Results
Date:5/9/2013

as $34.0 million and $25.5 million, respectively, an increase of $8.5 million. The increase primarily was due to higher legal, professional and outside service expenses. We also recognized higher stock compensation expense, primarily related to previously announced management departures.

Co-promotion expenses with Cubist for the quarters ended March 31, 2013 and 2012 were $3.8 million and $10.1 million, respectively, a decrease of $6.3 million. The co-promotion expenses for the quarter ended March 31, 2012 included an accrual of the first-year sales target bonus and an accrual of the first-year gross profit on sales above the sales target.

Net loss for the first quarter of 2013 was $31.3 million, or $0.65 cents per share, on a basic and diluted basis, as compared to net loss for the first quarter of 2012 of $10.9 million, or $0.23 cents per share, on a basic and diluted basis. The net loss in the year-ago quarter was favorably impacted by a $23.8 million gain on the deconsolidation of OBI.

At March 31, 2013, Optimer held cash, cash equivalents and short-term investments of $93.3 million. 

Optimer had 48.0 million shares outstanding on March 31, 2013.

"As we maintain our focus and commitment to establishing DIFICID as an important first-line treatment option for patients, we are similarly focused on conducting our review of strategic alternatives so that we can optimize value for our stockholders," continued Dr. McKinnell.

Conference Call and Webcast
The Company will host a conference call and webcast to discuss its first quarter 2013 financial results and provide a corporate update today at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers.  Please specify to the operator that you would like to join "Optimer's Financial Results Call." 
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
2. Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
3. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
4. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
5. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
6. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
7. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
10. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... -- LifeScienceIndustryResearch.com announces Global Angiographic X-ray ... pages along with 8 company profiles added to ... 2015 Market Research Report on Global Angiographic X-ray ... report on Global Angiographic X-ray System market.  For ... basic information including definition, classification, application, industry chain ...
(Date:3/1/2015)... 1, 2015 /CNW Telbec/ -   Ergoresearch Ltd (TSXV: ... and known under the « Équilibre, orthèses et ... quarter Ended on December 31, 2014. All dollar amounts ... Revenues for the second quarter of fiscal ... $ 4 095 112 decreasing by 8,8 % compared to revenues of ...
(Date:3/1/2015)... March 1, 2015  An innovative interventional radiology ... sufferers sustained relief of their headaches, according to ... Interventional Radiology ,s Annual Scientific Meeting . ... University New York Empire State College in Saratoga ... ganglion (SPG) blocks to give patients enough ongoing ...
Breaking Medicine Technology:Global Angiographic X-ray System Industry Research Report 2Global Angiographic X-ray System Industry Research Report 3Global Angiographic X-ray System Industry Research Report 4Global Angiographic X-ray System Industry Research Report 5Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
...  Boston Scientific Corporation (NYSE: BSX ) ... Chromium Coronary Stent System demonstrated non-inferior results in ... at one year compared to the PROMUS Element™ ... First Human Use Trial.  The trial reported one-year ...
... is pleased to announce the acquisition of Assured Packaging, ... custom manufacturer of aerosols for the health and beauty ... Assured Packaging acquisition and the purchase of K-G Spray-Pak ... most diversified custom aerosol filler in Canada. ...
Cached Medicine Technology:One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6PLZ Aeroscience Acquires Assured Packaging 2
(Date:3/2/2015)... WI (PRWEB) March 02, 2015 ... consultancy focused on quality, regulatory and technical consulting, ... as Chief Operating Officer. , Before joining ... experience leading R&D teams in all aspects of ... leadership positions at Covidien (Medtronic), Regulatory Compliance Associates ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 A true renaissance ... leader of the 1960s cult rock band Khazad Doom, has ... his determination to persevere despite all odds. His motto throughout ... matter what situation or goal was before him. And that ... is now being passed on to a new generation. , ...
(Date:3/2/2015)... 2015 In light of the FDA's ... Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide Legal ... for future users, but may come too late for ... the drug. The FDA has now included the term ... on Xarelto's label. The term “cytolytic hepatitis” has also ...
(Date:3/2/2015)... What are the best practices for writing ... are interviews scheduled, how can physicians best prepare, and ... practicing physicians who are looking for new opportunities can ... the PracticeLink Physician Career Advancement Workshop and Job Fair ... from 5:30 to 8:30 p.m. at the Marriott-Texas Medical ...
(Date:3/2/2015)... Bangladesh (PRWEB) March 02, 2015 The ... of fire safety expert Mark Chubb to serve as ... fire safety operations and training in Bangladesh and guide ... source. , “Mark will ensure that the Alliance ... fire safety programs for Bangladesh garment workers,” said Alliance ...
Breaking Medicine News(10 mins):Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... front of TV, computer linked to less bonding with peers, ... Too much time in front of computers or televisions increases ... parents and peers, a new study suggests. , The researchers ... who provided details about how they spent their free time ...
... resulting aspirin therapy, may not be needed for healthier patients ... study raises questions about the value of both the ankle-brachial ... blood vessel problems in the legs, and the common practice ... ankle-brachial index (ABI) measures blood pressure in the arm and ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... ...
... , ... , ... , , , , ... ...
Cached Medicine News:Health News:Screen Time May Take a Toll on Kids' Relationships 2Health News:Study Questions Value of Test for Peripheral Artery Disease 2Health News:Study Questions Value of Test for Peripheral Artery Disease 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 2Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 4Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 2Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 2Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 3
... Liquichek Qualitative Urine Toxicology Control is ... qualitative rapid urine drug screen panels, including ... (DOA) test kits like Bio-Rad TOX/See, Biosite ... includes qualitative results (+/) for popular kits ...
... Stain is an aqueous new ... in manual methods of reticulocyte ... a one year shelf life ... can be used in conjunction ...
... Liquichek ToRCH Plus IgM ... potential problems in your ToRCH ... affect your test results. Liquichek ... the perfect complement to Liquichek ...
... Liquichek ToRCH Plus Control is ... to monitor the performance of ... instruments and assays. A weak ... allow you to monitor the ...
Medicine Products: